Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 6.52
MYOS's Cash to Debt is ranked higher than
56% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. MYOS: 6.52 )
Ranked among companies with meaningful Cash to Debt only.
MYOS' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 6.52
Equity to Asset 0.81
MYOS's Equity to Asset is ranked higher than
78% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYOS: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
MYOS' s Equity to Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.87 Max: 0.96
Current: 0.81
0.17
0.96
F-Score: 4
Z-Score: -2.80
M-Score: -4.69
WACC vs ROIC
10.82%
-145.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1591.27
MYOS's Operating margin (%) is ranked lower than
96% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. MYOS: -1591.27 )
Ranked among companies with meaningful Operating margin (%) only.
MYOS' s Operating margin (%) Range Over the Past 10 Years
Min: -4642.42  Med: -332.79 Max: -128.6
Current: -1591.27
-4642.42
-128.6
Net-margin (%) -1600.90
MYOS's Net-margin (%) is ranked lower than
96% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. MYOS: -1600.90 )
Ranked among companies with meaningful Net-margin (%) only.
MYOS' s Net-margin (%) Range Over the Past 10 Years
Min: -5653.54  Med: -429.17 Max: -128.48
Current: -1600.9
-5653.54
-128.48
ROE (%) -96.60
MYOS's ROE (%) is ranked lower than
93% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. MYOS: -96.60 )
Ranked among companies with meaningful ROE (%) only.
MYOS' s ROE (%) Range Over the Past 10 Years
Min: -2665.24  Med: -117.33 Max: -88.51
Current: -96.6
-2665.24
-88.51
ROA (%) -76.28
MYOS's ROA (%) is ranked lower than
94% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. MYOS: -76.28 )
Ranked among companies with meaningful ROA (%) only.
MYOS' s ROA (%) Range Over the Past 10 Years
Min: -2600  Med: -80.95 Max: -45
Current: -76.28
-2600
-45
ROC (Joel Greenblatt) (%) -264.63
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. MYOS: -264.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -371466.67  Med: -738.82 Max: -205.82
Current: -264.63
-371466.67
-205.82
Revenue Growth (3Y)(%) -53.80
MYOS's Revenue Growth (3Y)(%) is ranked lower than
97% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MYOS: -53.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYOS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 144.7
Current: -53.8
0
144.7
EBITDA Growth (3Y)(%) -3.60
MYOS's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. MYOS: -3.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYOS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41  Med: 121.05 Max: 530.5
Current: -3.6
-41
530.5
EPS Growth (3Y)(%) -8.30
MYOS's EPS Growth (3Y)(%) is ranked lower than
71% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. MYOS: -8.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYOS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -19.05 Max: 530
Current: -8.3
0
530
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:RSPID, NAS:BNTC, AMEX:IGC, OTCPK:KAYS, OTCPK:NUVPF, OTCPK:PTLFD, OTCPK:AQSZF, NAS:DCTH, OTCPK:SPLIF, OTCPK:IMLFF, OTCPK:CYIG, NAS:CBYL, OTCPK:PUFXF, OTCPK:CVSI, OTCPK:ULUR, OTCPK:PCYN, OTCPK:TRGM, OTCPK:NRXGQ, OTCPK:RLMD, NAS:OCLS » details
MYOS Corp is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.

MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.

Ratios

vs
industry
vs
history
P/B 1.36
MYOS's P/B is ranked higher than
78% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. MYOS: 1.36 )
Ranked among companies with meaningful P/B only.
MYOS' s P/B Range Over the Past 10 Years
Min: 0.93  Med: 3.57 Max: 16.26
Current: 1.36
0.93
16.26
P/S 19.54
MYOS's P/S is ranked lower than
89% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. MYOS: 19.54 )
Ranked among companies with meaningful P/S only.
MYOS' s P/S Range Over the Past 10 Years
Min: 4.15  Med: 18.33 Max: 465.12
Current: 19.54
4.15
465.12
Current Ratio 4.30
MYOS's Current Ratio is ranked higher than
72% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. MYOS: 4.30 )
Ranked among companies with meaningful Current Ratio only.
MYOS' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 4.09 Max: 27.24
Current: 4.3
0.03
27.24
Quick Ratio 3.27
MYOS's Quick Ratio is ranked higher than
70% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. MYOS: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
MYOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.88 Max: 26.31
Current: 3.27
0.03
26.31
Days Inventory 596.05
MYOS's Days Inventory is ranked lower than
98% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. MYOS: 596.05 )
Ranked among companies with meaningful Days Inventory only.
MYOS' s Days Inventory Range Over the Past 10 Years
Min: 43.32  Med: 251.52 Max: 1919.9
Current: 596.05
43.32
1919.9
Days Sales Outstanding 7.70
MYOS's Days Sales Outstanding is ranked higher than
95% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. MYOS: 7.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.7  Med: 80.84 Max: 932.01
Current: 7.7
7.7
932.01
Days Payable 140.05
MYOS's Days Payable is ranked higher than
83% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. MYOS: 140.05 )
Ranked among companies with meaningful Days Payable only.
MYOS' s Days Payable Range Over the Past 10 Years
Min: 20.31  Med: 44.16 Max: 153.49
Current: 140.05
20.31
153.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
MYOS's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. MYOS: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.3  Med: -24.1 Max: -8.4
Current: -17.3
-32.3
-8.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.64
MYOS's Price/Net Cash is ranked higher than
82% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.90 vs. MYOS: 3.64 )
Ranked among companies with meaningful Price/Net Cash only.
MYOS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.28  Med: 7.52 Max: 34.02
Current: 3.64
2.28
34.02
Price/Net Current Asset Value 1.95
MYOS's Price/Net Current Asset Value is ranked higher than
90% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. MYOS: 1.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.55  Med: 5.82 Max: 80.17
Current: 1.95
1.55
80.17
Price/Tangible Book 1.84
MYOS's Price/Tangible Book is ranked higher than
74% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. MYOS: 1.84 )
Ranked among companies with meaningful Price/Tangible Book only.
MYOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.48  Med: 5.55 Max: 81.01
Current: 1.84
1.48
81.01
Price/Median PS Value 1.06
MYOS's Price/Median PS Value is ranked higher than
55% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. MYOS: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
MYOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 1.08 Max: 20.25
Current: 1.06
0.27
20.25
Earnings Yield (Greenblatt) (%) -101.79
MYOS's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MYOS: -101.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -154.84  Med: 181.1 Max: 74436.8
Current: -101.79
-154.84
74436.8

More Statistics

Revenue (TTM) (Mil) $0.33
EPS (TTM) $ -1.39
Beta1.26
Short Percentage of Float0.75%
52-Week Range $1.23 - 4.40
Shares Outstanding (Mil)5.08
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Sep 29 2016
8:03 am MYOS RENS Tech. Announces Publication of Fortetropin Human Clinical Trial Manuscript... Sep 29 2016
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Sep 29 2016
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Sep 07 2016
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Sep 07 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 31 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Aug 24 2016
MYOS RENS TECHNOLOGY INC. Financials Aug 20 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report Aug 12 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 08 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 29 2016
MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 Jun 22 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant May 20 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report May 13 2016
MYOS Reports Positive Results From Fortetropin(R) Clinical Study Apr 22 2016
MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 11 2016
MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: 2015 By the Numbers Apr 11 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 10-K, Annual Report Mar 30 2016
MYOS Corporation Announces Corporate Name Change to MYOS RENS Technology Inc. Mar 23 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Mar 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)